Lurbinectedin is a medication used to treat patients with metastatic small cell lung cancer who have progressed after previous treatments. However, there is limited information available on the use of Lurbinectedin during pregnancy. According to the FDA pregnancy category, Lurbinectedin may cause fetal harm when administered to a pregnant woman. There are no adequate and well-controlled studies in pregnant women, and it is unknown whether Lurbinectedin can cause fetal harm when administered to a pregnant woman or if it can affect reproductive capacity [2].

Based on the available information, Lurbinectedin should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Women of reproductive potential should use effective contraception during treatment with Lurbinectedin and for at least six months after the last dose [2].

In conclusion, the available information suggests that Lurbinectedin may cause fetal harm when administered to a pregnant woman. Therefore, it should only be used during pregnancy if the potential benefit justifies the potential risk to the fetus. Women of reproductive potential should use effective contraception during treatment with Lurbinectedin and for at least six months after the last dose [2].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/LURBINECTEDIN
[2] https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213702s000lbl.pdf
[3] https://www.zepzelca.com/